EQT acquires Igenomix, a global leader in women’s health and reproductive genetic services
· EQT to acquire Igenomix, one of the world’s leading biotechnology companies and a global leader in women’s health and reproductive genetic services for IVF (In Vitro Fertilization) clinics · Igenomix supports approximately 90,000 couples per year in their reproductive journey · EQT will support Igenomix’s continued international growth journey by leveraging EQT’s strong healthcare expertise, global platform and network of Industrial Advisors The EQT VIII fund (“EQT” or “EQT VIII”) has entered into an agreement to acquire Igenomix (“the Company”) from Charme Capital,